Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.
2024年8月14日，華盛頓，全球貨幣新聞社報道：鸚鵡螺體育公司（納斯達克：NAUT，以下簡稱「Nautilus」）是一家開拓性的單分子蛋白質組分析平台公司，今天宣佈該公司將參加摩根士丹利第22屆全球醫療保健大會，地點在紐約。
Nautilus management is scheduled to participate in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: .
鸚鵡螺體育管理層計劃於2024年9月4日上午7:00（美國東部時間）進行爐邊談話。有興趣的各方可以在公司網站的「投資者」部分上訪問演示文稿的實況和存檔網絡廣播。
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .
關於Nautilus Biotechnology，Inc。
Nautilus位於華盛頓州西雅圖市的公司總部和位於加利福尼亞州San Carlos的研究和開發總部，是一家開發階段的生命科學公司，致力於創建平台技術以量化和解鎖蛋白質組的複雜性。 鸚鵡螺體育的使命是通過民主化蛋白質組的獲取，並促進在人類健康和醫學方面的基本進展，從而改變蛋白質組學領域。 要了解更多關於鸚鵡螺體育，請訪問.
Media Contact
press@nautilus.bio
媒體聯繫人
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
投資者聯繫方式
investorrelations@nautilus.bio
譯文內容由第三人軟體翻譯。
